MedPath

Buprenorphine Detoxification - BBDVI - 19

Phase 2
Completed
Conditions
Opioid-Related Disorders
Registration Number
NCT00000237
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Brief Summary

The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Drug use
Retention
Weeks abstinent
Weeks continuous abstinence
Overall treatment outcome
Opioid dependence and psychiatric status
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Treatment Research Center

🇺🇸

Burlington, Vermont, United States

Treatment Research Center
🇺🇸Burlington, Vermont, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.